Bausch + Lomb Co. (NYSE:BLCO – Get Rating) – Research analysts at Jefferies Financial Group decreased their Q4 2022 earnings estimates for shares of Bausch + Lomb in a research report issued on Wednesday, November 2nd. Jefferies Financial Group analyst Z. Weiner now anticipates that the company will post earnings of $0.23 per share for the quarter, down from their previous forecast of $0.29. The consensus estimate for Bausch + Lomb’s current full-year earnings is $1.05 per share. Jefferies Financial Group also issued estimates for Bausch + Lomb’s FY2024 earnings at $1.17 EPS.
Several other equities research analysts have also recently weighed in on BLCO. Royal Bank of Canada reduced their target price on shares of Bausch + Lomb from $18.00 to $17.00 and set an “outperform” rating for the company in a research note on Thursday. JPMorgan Chase & Co. lowered their price target on shares of Bausch + Lomb from $16.00 to $15.00 and set a “neutral” rating for the company in a report on Thursday. HC Wainwright lowered their price target on shares of Bausch + Lomb from $21.00 to $20.00 and set a “buy” rating for the company in a report on Thursday. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $19.00 price objective (down from $22.00) on shares of Bausch + Lomb in a research note on Tuesday, August 30th. Finally, Morgan Stanley reduced their price target on shares of Bausch + Lomb from $19.00 to $18.00 and set an “equal weight” rating on the stock in a research report on Thursday. Four analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $22.54.
Bausch + Lomb Price Performance
Bausch + Lomb (NYSE:BLCO – Get Rating) last posted its earnings results on Thursday, August 4th. The company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.20 by $0.09. The business had revenue of $941.00 million for the quarter, compared to analyst estimates of $906.72 million.
Hedge Funds Weigh In On Bausch + Lomb
A number of large investors have recently modified their holdings of BLCO. River Road Asset Management LLC bought a new stake in Bausch + Lomb during the second quarter valued at approximately $2,153,000. Foundry Partners LLC bought a new position in Bausch + Lomb in the second quarter worth about $4,247,000. DekaBank Deutsche Girozentrale purchased a new stake in Bausch + Lomb in the second quarter worth about $1,016,000. Factorial Partners LLC purchased a new stake in shares of Bausch + Lomb during the second quarter valued at approximately $300,000. Finally, TD Asset Management Inc. purchased a new stake in Bausch + Lomb in the second quarter worth approximately $2,852,000. 10.32% of the stock is currently owned by institutional investors.
Bausch + Lomb Company Profile
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye.
- Get a free copy of the StockNews.com research report on Bausch + Lomb (BLCO)
- MarketBeat: Week in Review 10/31-11/4
- Is Hershey’s a Sweet Stock to Buy After a Post-Earnings Dip?
- Datadog Doesn’t Belong In The Doghouse
- Nikola Shares Fall Even As EV Maker Beats Q3 Expectations
- Mixed Results Actually Bring More Optimism than Risk for AMD
Receive News & Ratings for Bausch + Lomb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch + Lomb and related companies with MarketBeat.com's FREE daily email newsletter.